The ETS family of oncogenic transcription factors in solid tumours
Findings over the past decade have identified aberrant activation of the ETS transcription
factor family throughout all stages of tumorigenesis. Specifically in solid tumours, gene …
factor family throughout all stages of tumorigenesis. Specifically in solid tumours, gene …
[HTML][HTML] Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies
Background Poly-(ADP-Ribose)-Polymerase (PARP) inhibitors are becoming important
actors of anti-neoplasic agents landscape, with recent but narrow FDA's approvals for …
actors of anti-neoplasic agents landscape, with recent but narrow FDA's approvals for …
[HTML][HTML] The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc
Long non-coding RNAs (lncRNAs) represent an emerging layer of cancer biology,
contributing to tumor proliferation, invasion, and metastasis. Here, we describe a role for the …
contributing to tumor proliferation, invasion, and metastasis. Here, we describe a role for the …
Development and validation of a novel radiosensitivity signature in human breast cancer
C Speers, S Zhao, M Liu, H Bartelink, LJ Pierce… - Clinical Cancer …, 2015 - AACR
Purpose: An unmet clinical need in breast cancer management is the accurate identification
of patients who will benefit from adjuvant radiotherapy. We hypothesized that integration of …
of patients who will benefit from adjuvant radiotherapy. We hypothesized that integration of …
[HTML][HTML] The human VRK1 chromatin kinase in cancer biology
I Campillo-Marcos, R García-González… - Cancer letters, 2021 - Elsevier
VRK1 is a nuclear Ser-Thr chromatin kinase that does not mutate in cancer, and is
overexpressed in many types of tumors and associated with a poor prognosis. Chromatin …
overexpressed in many types of tumors and associated with a poor prognosis. Chromatin …
Epigenetic mechanisms underlying prostate cancer radioresistance
C Macedo-Silva, R Benedetti, F Ciardiello… - Clinical …, 2021 - Springer
Radiotherapy (RT) is one of the mainstay treatments for prostate cancer (PCa), a highly
prevalent neoplasm among males worldwide. About 30% of newly diagnosed PCa patients …
prevalent neoplasm among males worldwide. About 30% of newly diagnosed PCa patients …
PARP1 inhibition radiosensitizes models of inflammatory breast cancer to ionizing radiation
Sustained locoregional control of disease is a significant issue in patients with inflammatory
breast cancer (IBC), with local control rates of 80% or less at 5 years. Given the …
breast cancer (IBC), with local control rates of 80% or less at 5 years. Given the …
A novel small molecule inhibitor of the DNA repair protein Ku70/80
E Weterings, AC Gallegos, LN Dominick, LS Cooke… - DNA repair, 2016 - Elsevier
Abstract Non-Homologous End-Joining (NHEJ) is the predominant pathway for the repair of
DNA double strand breaks (DSBs) in human cells. The NHEJ pathway is frequently …
DNA double strand breaks (DSBs) in human cells. The NHEJ pathway is frequently …
PARP inhibitors in prostate cancer
P Ramakrishnan Geethakumari, MJ Schiewer… - … treatment options in …, 2017 - Springer
Opinion Statement The genomic landscape of metastatic prostate cancer (mPCa) reveals
that up to 90% of patients harbor actionable mutations and> 20% have somatic DNA repair …
that up to 90% of patients harbor actionable mutations and> 20% have somatic DNA repair …
[HTML][HTML] UHRF2 promotes the malignancy of hepatocellular carcinoma by PARP1 mediated autophagy
Y Zhang, K Wu, Y Liu, S Sun, Y Shao, Q Li, X Sui… - Cellular …, 2023 - Elsevier
Autophagy have critical implications in the proliferation and metastasis of HCC. In the
current study, we aimed to explore the underlying mechanisms of UHRF2 regulates HCC …
current study, we aimed to explore the underlying mechanisms of UHRF2 regulates HCC …